President Donald Trump is seeking to bring health-research funding under his direct control, according to a report published by Politico on Tuesday and relayed by HuffPost.

The report, which cites unnamed sources familiar with the administration's planning, describes an effort to centralize authority over the federal health-research budget — a portfolio that has historically flowed through the National Institutes of Health and peer-review structures designed to insulate scientific decisions from political direction.

For R&D managers at universities, teaching hospitals and independent institutes, the stakes are operational, not abstract. NIH distributes the bulk of federal biomedical research money through competitive grants that anchor lab payrolls, equipment purchases and multi-year study budgets. Any move to route funding decisions through the White House would place those decisions inside a political chain of command rather than the existing study-section process, in which panels of working scientists score proposals before dollars move.

The Politico report does not specify which agencies, grant mechanisms or dollar amounts fall inside the proposed restructuring. HuffPost's summary likewise offers no figures. That absence matters: the NIH budget for the current fiscal year runs to roughly $48 billion across more than 50,000 awards, and the practical consequences of centralized control would differ sharply depending on whether the plan targets new awards, renewals, or the broader appropriations pipeline that Congress controls.

What the reporting does establish is intent. The administration has already demonstrated willingness to reshape research-funding terms this term — including earlier attempts to cap indirect-cost reimbursement rates that universities say cover the real overhead of running federally supported science. Indirect-cost caps, grant pauses and terminations have each forced institutions to re-budget mid-cycle, freezing hiring and delaying equipment orders. A formal transfer of award authority to the executive would extend that leverage from individual decisions to the system as a whole.

Researchers planning submissions should treat the report as a planning signal rather than a settled policy. No executive order, agency directive or budget document has been published alongside the reporting, and any structural change to how health-research funds are awarded would face legal challenges from universities and research associations that have sued successfully over earlier funding interventions this term.

Institutions with large NIH portfolios — Johns Hopkins, the University of Michigan, the University of California system among them — have already built contingency planning around federal funding volatility, including scenario budgets that assume flat or reduced federal support through the remainder of the administration. Grant administrators at several institutions have advised principal investigators to accelerate spending on approved awards and to diversify submission pipelines toward foundations and industry partnerships.

The unnamed sources cited by Politico indicate the effort is underway at the White House, but the report does not state a timeline, an implementing mechanism, or whether relevant Cabinet officials support the plan. HHS Secretary Robert F. Kennedy Jr., who oversees NIH, has not publicly commented on the proposal as of the report's publication.

Watch for the concrete markers that would confirm or kill the plan: an Office of Management and Budget circular reassigning grant authority, language in the president's next budget request, or litigation filings from the Association of American Universities and peer organizations.